使用随机生存森林进行竞争性风险分析,对末期脏病的动态生存预测
Daniel Christiadi1,2,3, Kevin Chai4, Aaron Chuah1
1Department of Immunology and Infectious Disease, John Curtin School of Medical Research, Australian National University, Canberra, ACT, Australia.
Frontiers in medicine
|December 26, 2024
概括
一个新的动态模型使用纵向患者数据预测末期病 (ESKD),改进了静态模型,以更好地管理慢性病 (CKD) 和透析计划.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 生物统计学 生物统计学
- 预测建模预测建模
背景情况:
- 静态模型无法捕捉慢性病 (CKD) 进展中的疾病异质性.
- 纵向数据为预测器轨迹提供了更细致的观点.
- 预测末期病 (ESKD) 需要动态方法.
研究的目的:
- 开发和验证ESKD的动态生存预测模型.
- 纳入纵向临床病理学数据以提高准确性.
- 解决死亡作为CKD进展的竞争风险.
主要方法:
- 使用了与随机生存森林的标志性方法.
- 优化了模型的5年预测时间.
- 使用累积发病率函数 (CIF) 生成个性化的动态预测图.
主要成果:
- 该模型是用4950名患者开发的,在8729名患者中得到了验证.
- 已确定六个关键变量 (年龄,白蛋白,二碳酸盐,化物,eGFR,血红蛋白) 用于减少模型.
- 实现了强大的预测性能:ESKD的中位数一致性指数为84.84%,死亡为84.1%.
结论:
- 成功开发并验证了ESKD的动态预测模型.
- 该模型使用易于获得的纵向临床病理学数据.
- 旨在帮助临床医生为慢性病患者进行主动透析计划.
相关概念视频
Survival Tree
39
Survival trees are a non-parametric method used in survival analysis to model the relationship between a set of covariates and the time until an event of interest occurs, often referred to as the "time-to-event" or "survival time." This method is particularly useful when dealing with censored data, where the event has not occurred for some individuals by the end of the study period, or when the exact time of the event is unknown.
Building a Survival Tree
Constructing a...
Building a Survival Tree
Constructing a...
39
Comparing the Survival Analysis of Two or More Groups
83
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
83
Cancer Survival Analysis
291
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
291
Kaplan-Meier Approach
52
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
52
Censoring Survival Data
40
Survival analysis is a statistical method used to analyze time-to-event data, often employed in fields such as medicine, engineering, and social sciences. One of the key challenges in survival analysis is dealing with incomplete data, a phenomenon known as "censoring." Censoring occurs when the event of interest (such as death, relapse, or system failure) has not occurred for some individuals by the end of the study period or is otherwise unobservable, and it might have many different...
40
Actuarial Approach
39
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
39


